Next Biomedical Co.,Ltd (389650) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Next Biomedical Co.,Ltd stock KRW 18,952, price KRW 23,800, that is 20.4% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Next Biomedical Co.,Ltd
389650 · KQExpensive (fair value 20% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
27‑month range 23,700 KRW – 98,000 KRW · fair‑value band 14,214 KRW – 23,689 KRW · the 23,800 KRW price screens above the 18,952 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Next Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization.
Show moreShow less
The company was founded in 2014 and is based in Incheon, South Korea.
Stock analysis
Next Biomedical Co.,Ltd (389650) currently trades at 23,800 KRW, while our estimate is 18,952 KRW, 20% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 14,214 KRW (bear) to 23,689 KRW (bull), the price of 23,800 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Next Biomedical Co.,Ltd reported revenue of 16.5B KRW in FY2025 versus 2.3B KRW in FY2021, a compound +64.2%/yr. Reported net income was −311M KRW in FY2025.
Key figures
Market cap 197B KRW (≈ $147M) Micro · P/S ratio 12.6 · EPS (TTM) 28.10 KRW · Net margin 1.3% · Return on equity 0.5% · Return on assets (EBIT) −11.4% (5-year average) · Operating margin −21.0% · Revenue (TTM) 17.8B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).
What moves the price
The share trades about 76% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −20%, 389650 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Next Biomedical Co.,Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- Stock screener with 62 metrics
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 389650 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 389650 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 389650 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 389650 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 389650 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 389650 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 389650 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 389650 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 389650 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 389650 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Next Biomedical Co.,Ltd (389650) overvalued or undervalued?
What is the fair value of 389650?
What is the quality score of 389650?
What is the price target for Next Biomedical Co.,Ltd (389650)?
What is the Next Biomedical Co.,Ltd stock forecast for 2026?
What is the revenue of Next Biomedical Co.,Ltd (389650)?
What is the intrinsic value of Next Biomedical Co.,Ltd (389650)?
Is Next Biomedical Co.,Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 389650?
How much is Next Biomedical Co.,Ltd worth?
What do the bullish and bearish scenarios say about 389650?
How solid is the balance sheet of Next Biomedical Co.,Ltd (389650)?
How far is 389650 from its 52-week high?
Which stocks are comparable to Next Biomedical Co.,Ltd?
Is Next Biomedical Co.,Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Next Biomedical Co.,Ltd (389650)?
What should I pay attention to with Next Biomedical Co.,Ltd right now?
Key figures of Next Biomedical Co.,Ltd
How large is the market capitalisation of Next Biomedical Co.,Ltd (389650)?
What is the P/S ratio of Next Biomedical Co.,Ltd (389650)?
What are the earnings per share of Next Biomedical Co.,Ltd (389650)?
What is the net margin of Next Biomedical Co.,Ltd (389650)?
What is the return on equity of Next Biomedical Co.,Ltd (389650)?
What is the EBIT return on assets of Next Biomedical Co.,Ltd (389650)?
What is the operating margin of Next Biomedical Co.,Ltd (389650)?
How fast is revenue growing at Next Biomedical Co.,Ltd (389650)?
How much free cash flow does Next Biomedical Co.,Ltd (389650) generate?
How much net debt does Next Biomedical Co.,Ltd (389650) carry?
Watch Next Biomedical Co.,Ltd in the live analysis
One click puts Next Biomedical Co.,Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.